Scholars Central

Conference abstractPublished 8 Jun 2018

Navigating government healthcare reforms and their impact in USA, Europe, Turkey & emerging markets

Authors: Yavuz Selim Silay

Istanbul Consulting Group, Turkey

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pharmaceutical, Biotech and Medical Device companies are constantly evaluating how decisions at the US ,Europe, Turkey and emerging markets are taken at the federal and state level and how it will impact provider and patient access and coverage to their therapies. To gain these critical insights, government affairs & medical affairs teams require speaking with those on the frontlines of healthcare delivery - physicians, allied healthcare professionals, payers, and patients. New generation government engagement and commercial diplomacy approach developed by ICG ( Istanbul Consulting Group) will be provided with unique cases. Dr. Yavuz Selim SILAY a global leader and seasoned expert in government engagement, commercial diplomacy, corporate communications, government affairs & medical affairs will discuss how companies utilizing government affairs and medical affairs teams should engage decision makers, payers, physicians and acquire these insights in a convenient, costeffective, and compliant manner in this current changing global regulatory landscape.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Yavuz Selim Silay”